Biotech innovators are pioneering RNA‑optimized fusions for targeted alpha therapies (TATs), positioning themselves as first‑movers in the broader radiopharma market that is exploding with demand for precision cancer killers.
Radiopharma Market Momentum Builds Billions
The radiopharma sector, blending alpha‑particle precision with smart targeting molecules and sophisticated imaging, is barreling toward multibillion‑dollar territory over the next decade as oncology budgets tilt decisively toward precision radiopharmaceuticals. Forecasts call for robust double‑digit annual growth as oncologists look beyond chemotherapy and small molecules toward theranostic approaches that pair diagnostic scans with therapeutic radioisotopes in a single platform.
Pipeline Pioneers Lead the Radiopharma Charge
Orano Med has emerged as one of the early radiopharma torchbearers, pushing lead‑212 alpha radioligand therapies into Phase I for GRPR‑expressing solid tumors while expanding collaborations with Roche to support broader development. Fusion Pharmaceuticals is advancing its clinical franchise in prostate cancer, with Phase II programs designed to show how alpha‑emitting radiopharmaceuticals can deepen responses in heavily pretreated patients. RayzeBio, now under a larger pharma umbrella, continues to move its candidate RYZ101 through late‑stage development in neuroendocrine tumors after encouraging activity in patients who have failed lutetium‑177 therapy, while Aktis Oncology is driving first‑in‑human programs against Nectin‑4 and other solid‑tumor targets as it kicks off 2026’s biotech IPO cycle.
NAYA Therapeutics: Astatine‑211 Specialist
Within that universe, targeted alpha therapies represent the sharpest edge of radiopharma, and investors are betting that platforms like NAYA’s Astatine‑211 franchise could outpace beta‑emitter rivals in efficacy and durability. Indeed, NAYA Therapeutics is carving out a differentiated position by centering its pipeline on Astatine‑211, a so‑called “goldilocks” alpha emitter prized for its short half‑life, clean decay, chelator‑free chemistry, and scalable production from naturally abundant bismuth‑209. Its lead targeted alpha therapy, NY‑703, is a GPC3‑targeting Astatine‑211 radiopharmaceutical aimed at residual and metastatic hepatocellular carcinoma (HCC), with investigator‑initiated clinical trials slated to begin in China in 2026 under a supply partnership with Alpha Nuclide’s TR‑Alpha cyclotron facility near Shanghai. NAYA is simultaneously expanding its HCC franchise with NY‑700, a first‑in‑class GPC3‑targeted NAYA Therapeutics now sits squarely in this first‑wave cohort, bringing a next‑generation Astatine‑211 platform to a space where valuations are already drifting toward unicorn territory and strategic acquirers are circling. Astatine‑211 alpha radioimmunotherapy, complementing bifunctional antibody programs NY‑303 (GPC3/NKp46/CD16 NK‑cell engager) and NY‑500 (PD‑1/VEGF) that cover second‑line and first‑line HCC, respectively, plus NY‑338 for multiple myeloma.
NAYA’s strategy hinges on two synergistic modalities—Astatine‑211 targeted alpha therapies and bifunctional antibodies—that can be deployed alone or in combination across the HCC disease continuum. To make that ambition practical, the company has stitched together a decentralized manufacturing and supply network through partnerships with Atley Solutions in Europe and IONETIX in the US, using Atley’s C100 modules and new cyclotron capacity to bring clinical‑grade Astatine‑211 production closer to outpatient centers. It is a quietly radical move: instead of treating radionuclide supply as a constraint, NAYA is turning it into a competitive moat, potentially smoothing its path to commercialization and making its platform look decidedly M&A‑ready.
RNA Fusion: The Next‑Gen Edge in Radiopharma
Layered on top of the radiopharma renaissance is a new wave of RNA‑optimized and immune‑engaging constructs designed to sharpen how and where alpha emitters are deployed. Programmable RNA 2.0 architectures aim to improve stability, reduce immunogenicity, and fine‑tune expression so that radiolabeled payloads and immune‑engaging antibodies find cancer cells with almost GPS‑level precision, turning TATs into programmable radiopharma engines rather than static drugs. The result is a therapeutic profile that tries to marry the elegant logic of mRNA and next‑gen biologics with the brute‑force lethality of alpha particles—essentially giving oncologists a molecular scalpel with the stopping power of a sledgehammer. Regulators are sketching frameworks for more personalized gene, cell, and radiopharmaceutical therapies, adding institutional validation to the modality and giving early movers like NAYA a regulatory tailwind.
Investor Appetite Peaks in Radiopharma IPOs
On the capital‑markets front, radiopharma has graduated from speculative curiosity to seemingly a must‑have exposure for oncology‑focused funds, with targeted alpha therapy viewed as the high‑octane growth engine inside that theme. Companies with assets as early as Phase I are securing billion‑dollar post‑money valuations, justified by strong clinical signals, scarcity value in high‑quality TAT platforms, and a growing roster of big‑pharma buyers hungry to bulk up their oncology pipelines. Recent IPOs and follow‑on offerings—such as those funding Nectin‑4 and PSMA‑directed radiopharmaceuticals—have priced at the upper end of their ranges, with oversubscribed books suggesting that generalists are now joining the specialists at the radiopharma table.
In that context, NAYA’s Astatine‑211‑centric pipeline, fortified by global manufacturing partnerships and a comprehensive HCC franchise, potentially positions the company as a plausible future entrant into the radiopharma unicorn club—or as a tempting acquisition target for big pharma players looking to bolt on a ready‑made alpha therapy platform. For investors willing to stomach biotech volatility, the category offers something rare in oncology: a clear mechanistic edge, an expanding body of real‑world evidence, and a strategic M&A backdrop where “radioactive” is starting to sound less like a risk label and more like a valuation strategy.
Key Radiopharma Investments and Acquisitions
- Orano Med – Phase I
- $1.9 billion Series B post‑money valuation in 2025 underscores how early‑stage alpha‑therapy platforms can command near‑unicorn pricing before pivotal data
- Backing from a global pharma partner validates the technology and signals strong strategic interest in securing long‑term radiopharma optionality.
- Fusion – Phase II (acquired by AstraZeneca, AZN)
- $2.4 billion acquisition in 2024 highlights big pharma’s willingness to pay a premium for clinical‑stage targeted alpha assets with de‑risked mechanisms
- The deal effectively set a benchmark for later transactions, anchoring valuation expectations across the alpha‑therapy peer group.
- Mariana Oncology – Pre‑clinical (acquired by Novartis, NVS)
- $1.75 billion pre‑clinical acquisition in 2025 shows that well‑positioned platforms can leapfrog the traditional “wait for Phase II” hurdle.
- Novartis’ move reinforces the idea that radiopharma pipelines are now viewed as strategic infrastructure, not just product bets.
- RayzeBio – Phase I (acquired by Bristol Myers Squibb, BMY)
- $4.1 billion acquisition in 2025 stands out as the marquee transaction, effectively re‑rating the entire targeted radiopharma category.
- BMS secured both clinical programs and manufacturing know‑how, illustrating how integrated capabilities drive top‑tier deal values.
- Aktis – Phase I IPO
- $1.25 billion IPO post‑money valuation in 2026 demonstrates that public markets will fund early‑stage alpha‑therapy stories at unicorn levels.
- Aktis’ listing provides a liquid valuation marker for private peers and a roadmap for companies weighing IPO versus M&A exits.
The Sources
- Targeted Alpha-Therapy Market Size, Trends Report 2026 – The Business Research Company
https://www.thebusinessresearchcompany.com/report/targeted-alpha-therapy-global-market-report[thebusinessresearchcompany] - Targeted Alpha Therapy Market Report – Strategic Market Research
https://www.strategicmarketresearch.com/market-report/targeted-alpha-therapy-market[strategicmarketresearch] - Targeted Alpha Therapies Market to Grow at 44% CAGR – BCC Research
https://www.bccresearch.com/pressroom/phm/targeted-alpha-therapies-market-to-grow-at-44-cagr[bccresearch] - Targeted Alpha Therapies Market to Grow at 44% CAGR Globally – Yahoo Finance
https://finance.yahoo.com/news/targeted-alpha-therapies-market-grow-180600868.html[finance.yahoo] - Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR – Orano Med
https://www.oranomed.com/en/resources/news/2023/orano-med-starts-phase-1-trial-with-alpha-radioligand-therapy-212pb-grpr-in-patients[oranomed] - Orano Med Enters Next Phase of Collaboration With Roche – Yahoo Finance
https://finance.yahoo.com/news/orano-med-enters-next-phase-104800407.html[finance.yahoo] - Fusion Pharmaceuticals Announces First Patient Dosed in Phase 2 Portion of AlphaBreak Trial – BioSpace
https://www.biospace.com/press-releases/fusion-pharmaceuticals-announces-first-patient-dosed-in-the-phase-2-portion-of-the-alphabreak-trial[biospace] - Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates – BioSpace
https://www.biospace.com/fusion-pharmaceuticals-announces-clinical-program-and-manufacturing-updates[biospace] - Phase 1b Portion of the ACTION-1 Trial of RYZ101 – ASCO/RayzeBio (PDF)
https://rayzebio.com/wp-content/uploads/2024/06/Halperin-ACTION-1-ASCO-2024-Poster-UPLOAD.pdf[rayzebio] - GEP-NETs – RayzeBio Pipeline Overview
https://rayzebio.com/pipeline/gep-nets/[rayzebio] - Assessing the Platform’s S-Curve Potential in Targeted Alpha Therapy – Aktis Oncology Coverage
https://www.ainvest.com/news/aktis-oncology-assessing-platform-curve-potential-targeted-alpha-therapy-2602/[ainvest] - Aktis Oncology Kicks 2026 IPO Cycle Off With $210m Target – Pharmaceutical Technology
https://www.pharmaceutical-technology.com/news/aktis-oncology-kicks-2026-ipo-cycle-off-with-210m-target/[pharmaceutical-technology] - Aktis Oncology Aims for $209M Windfall From First Biotech IPO of 2026 – Fierce Biotech
https://www.fiercebiotech.com/biotech/aktis-oncology-aims-209m-windfall-1st-biotech-ipo-2026[fiercebiotech] - Programmable RNA 2.0: Beyond the First mRNA Revolution – BioSpace
https://www.biospace.com/business/programmable-rna-2-0-beyond-the-first-mrna-revolution[biospace] - The Limitless Future of RNA Therapeutics – Nature Reviews Drug Discovery (PMC)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8012680/[pmc.ncbi.nlm.nih] - Alliance for mRNA Medicines Welcomes New FDA Framework – mRNAMedicines.org
https://mrnamedicines.org/alliance-for-mrna-medicines-welcomes-new-fda-framework-to-accelerate-development-of-personalized-gene-and-cell-therapies[mrnamedicines] - Next Generation Targeted Alpha Therapy Clinical Trials and Development Insight – BioSpace
https://www.biospace.com/press-releases/next-generation-targeted-alpha-therapy-clinical-trials-development-insight[biospace] - Oncology Market Set to Nearly Triple: Five Companies Leading the Charge – Yahoo Finance
https://finance.yahoo.com/news/oncology-market-set-nearly-triple-3026959[prnewswire] - Astatine‑211 Targeted Alpha Therapies – NAYA Therapeutics
https://www.nayatx.com/astatine-211-targeted-alpha-therapies[nayatx] - NAYA Therapeutics Expands Its Hepatocellular Carcinoma (HCC) Pipeline With NY‑700 – Access Newswire
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-expands-its-hepatocellular-carcinoma-hcc-pipeline-with-ny-700[accessnewswire] - NAYA Therapeutics Partners With Atley Solutions on Astatine‑211 Radiopharmaceuticals – Pharma Industrial India
https://www.pharmaindustrial-india.com/news/naya-therapeutics-partners-with-atley-solutions-on-astatine-211-radio-pharmaceuticals[pharmaindustrial-india] - NAYA Therapeutics Partners With IONETIX to Build a US Production Network for Astatine‑211 – FirstWord Pharma
https://firstwordpharma.com/story/5991246[firstwordpharma] - NAYA Announces Partnership With Alpha Nuclide to Support Clinical Development of NY‑703 in China – Access Newswire
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-announces-partnership-with-alpha-nuclide-to-support-clinical-development[accessnewswire] - NAYA Therapeutics Partners With Alpha Nuclide to Advance Astatine‑211 Therapy – MedPath
https://trial.medpath.com/news/e4c6693261bb40b5/naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-therapy[trial.medpath] - Naya Therapeutics Unveils GPC3‑Targeted Astatine‑211 Radioimmunotherapy – BioWorld
https://www.bioworld.com/articles/721292-naya-therapeutics-unveils-gpc3-targeted-astatine-211-radioimmunotherapy[bioworld] - NAYA Therapeutics Appoints Jason D. Hurt, MD, MBA, as Chief Medical Officer – Access Newswire
https://markets.chroniclejournal.com/chroniclejournal/article/accwirecq-2026-2-17-naya-therapeutics-appoints-jason-d-hurt-md-mba-as-chief-medical-officer[markets.chroniclejournal] - NAYA Therapeutics to Present at the Network for Optimized Astatine‑Labeling (NOARL) – Access Newswire
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-to-present-at-the-network-for-optimized-astatine-labeling[accessnewswire]
